"Now, this is something we are still gaining data on, but most recent data looking at convalescent sera of Covid-19 cases in people who received Covaxin, it was found to neutralise the 617 variant," Fauci was quoted as saying during the White House press briefing
This message was conveyed to Chief Secretary Somesh Kumar who held a meeting with Dr. Krishna Ella, MD, Bharat Biotech on Tuesday at BRKR Bhavan following directions from Chief Minister K. Chandrashekar Rao.
Bharat Biotech CMD Krishna M Ella said the company is supplying the vaccine to the Central Government at Rs 150 per dosage
Safety and efficacy results from the final analysis will be available in June and the final report will be submitted to a peer-reviewed publication, says Bharat Biotech
The top research institute said that “NIV has also demonstrated the neutralisation potential of Covaxin against the UK and Brazil variants.”
Hyderabad-based vaccine maker implements expansion across multiple facilities in Hyderabad and Bengaluru to reach about 700 million doses per year capacity
"The agreement with Precisa Medicamentos is based on a long term partnership and will continue,” Bharat Biotech stated.
Soon after the outbreak, the industry quickly adapted to the supply chain needs and manpower scenario and got into making generic drugs and vaccine development.
The study showed that 54 per cent of the population in the city has antibodies, which means they have developed immunity to SARS-CoV-2 virus
The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement.
Both SII and Bharat Biotech are involved in producing Covid-19 vaccine
However, the union health ministry would take a final call on the proposition.
Hyderabad-based vaccine maker to supply 20 million doses of Covaxin during the second and third quarters of 2021
The representatives from the Central Asian nation of 41 million people took a tour of the world-class Bio-Safety Level 3 manufacturing facility.
Life sciences sector in Telangana attracted investments to the tune of about Rs 3,700 crores in last one year with an employment potential for around 14,000 people
Dr Krishna M Ella, CMD and Suchitra Ella, joint managing director, Bharat Biotech International will receive the award on February 22, during the inaugural event of BioAsia 2021.
2,77,825 inoculated as first phase of vaccine drive in State concludes
Under the terms of the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including emergency use authorisation (EUA)) and commercialisation for the US market.